Contact: [email protected]
| Title | Tumor type | Line | Study information |
|---|---|---|---|
| PEACE III | prostate | ≥1L | Enzalutamide +/- Ra223 in castration resistant prostate cancer with ≥2 bone M+ |
| KEYNOTE-676 | Non-muscle invasive bladder carcinoma | Persistent or recurrent following BCG induction | Pembrolizumab + BCG |